TW200526588A - Chemical compounds - Google Patents

Chemical compounds Download PDF

Info

Publication number
TW200526588A
TW200526588A TW093134800A TW93134800A TW200526588A TW 200526588 A TW200526588 A TW 200526588A TW 093134800 A TW093134800 A TW 093134800A TW 93134800 A TW93134800 A TW 93134800A TW 200526588 A TW200526588 A TW 200526588A
Authority
TW
Taiwan
Prior art keywords
methyl
phenyl
amino
oxy
carbonyl
Prior art date
Application number
TW093134800A
Other languages
English (en)
Chinese (zh)
Inventor
Nicolas Eric Faucher
Paul Martres
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0326747A external-priority patent/GB0326747D0/en
Priority claimed from GB0329462A external-priority patent/GB0329462D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of TW200526588A publication Critical patent/TW200526588A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW093134800A 2003-11-17 2004-11-12 Chemical compounds TW200526588A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0326747A GB0326747D0 (en) 2003-11-17 2003-11-17 Chemical compounds
GB0329462A GB0329462D0 (en) 2003-12-19 2003-12-19 Chemical compounds

Publications (1)

Publication Number Publication Date
TW200526588A true TW200526588A (en) 2005-08-16

Family

ID=34621661

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093134800A TW200526588A (en) 2003-11-17 2004-11-12 Chemical compounds

Country Status (9)

Country Link
US (1) US20080021030A1 (https=)
EP (1) EP1685113B1 (https=)
JP (1) JP2007511485A (https=)
AR (1) AR046625A1 (https=)
AT (1) ATE402926T1 (https=)
DE (1) DE602004015498D1 (https=)
ES (1) ES2311179T3 (https=)
TW (1) TW200526588A (https=)
WO (1) WO2005049578A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064682A1 (en) * 2004-07-01 2008-03-13 Daiichi Pharmaceutical Co., Ltd. Pyrazole Derivatives
RU2007135745A (ru) * 2005-02-28 2009-04-10 Ниппон Кемифар Ко., Лтд. (JP) АКТИВАТОР δ- РЕЦЕПТОРА, АКТИВИРУЕМОГО ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМЫ
US8703805B2 (en) * 2005-06-27 2014-04-22 Exelixis Patent Company Llc Modulators of LXR
CN101466687B (zh) 2006-04-18 2012-04-11 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Lxr 및 fxr 조절자
JP2010523623A (ja) * 2007-04-11 2010-07-15 グラクソ グループ リミテッド P2x7調節因子としてのピラゾール誘導体
MX2010011252A (es) 2008-04-15 2010-11-30 Nippon Chemiphar Co Activador para el receptor activado por el proliferador de peroxisoma.
WO2010058858A1 (ja) * 2008-11-21 2010-05-27 ラクオリア創薬株式会社 5-ht2b受容体拮抗活性を有する新規ピラゾール-3-カルボキサミド誘導体
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
KR101758201B1 (ko) * 2009-12-15 2017-07-14 바이엘 크롭사이언스 악티엔게젤샤프트 1-알킬-/1-아릴-5-피라졸카복실산 유도체의 제조방법
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
CN101870676B (zh) * 2010-06-24 2011-09-07 山东大学 1-(2-肟基-2-苯基乙基)-3-苯基-1h-吡唑-5-甲酸乙酯衍生物及其制备与应用
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
CN110087667A (zh) 2016-08-16 2019-08-02 隐形生物治疗公司 Elamipretide的基于N-羧基酸酐的规模合成
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
MX2020010433A (es) 2018-04-04 2020-10-28 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.
JP2021528405A (ja) * 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレータとしてのアミド置換チアゾール
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
IL135177A0 (en) * 1997-10-02 2001-05-20 Sankyo Co Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
HK1045991B (en) * 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP3372923B2 (ja) * 2000-02-25 2003-02-04 エヌイーシーマイクロシステム株式会社 半導体集積回路
US7319104B2 (en) * 2002-03-01 2008-01-15 Smithkline Beecham Corporation hPPARs activators

Also Published As

Publication number Publication date
JP2007511485A (ja) 2007-05-10
ES2311179T3 (es) 2009-02-01
ATE402926T1 (de) 2008-08-15
DE602004015498D1 (de) 2008-09-11
EP1685113B1 (en) 2008-07-30
WO2005049578A1 (en) 2005-06-02
US20080021030A1 (en) 2008-01-24
AR046625A1 (es) 2005-12-14
EP1685113A1 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
TW200526588A (en) Chemical compounds
US10344016B2 (en) Bromotriazole intermediates
KR101021828B1 (ko) 2 이상의 치환기를 갖는 벤젠 화합물
CN102834382B (zh) 作为钙释放激活钙通道调节剂的吡唑衍生物
CN102656168B (zh) 作为溶血磷脂酸受体拮抗剂的多环化合物
JP5432890B2 (ja) 複素環誘導体及びその用途
TWI262185B (en) Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
ES2320320T3 (es) Nuevos compuestos de isoxazol y tiazol y uso de los mismos como farmacos.
AU781141B2 (en) Novel use of phenylheteroalkylamine derivatives
JP4602672B2 (ja) プロスタグランジンf受容体のモジュレーターとしてのチアゾリジンカルボキサミド誘導体
JP2002500619A (ja) 置換ビフェニルイソオキサゾールスルホンアミド
HK1206339A1 (en) N-aryltriazole compounds as lpar antagonists
TW200416029A (en) Agent for preventing or treating neuropathy
JP2016135778A (ja) シアノトリアゾール化合物の医薬用途
JP2008507528A (ja) 置換ピラゾール、このような化合物を含有する組成物及び使用方法
CN104411690A (zh) 作为lpar拮抗剂的取代的吡唑化合物
TWI537257B (zh) 連續芳環化合物
JP2008510815A (ja) 血栓症および心臓血管疾患の治療にて有用な調節剤であるプラスミノゲン活性化因子阻害剤1型(pai−1)としてのオキサゾロ−ナフチル酸
WO1990005132A1 (fr) Derives d'allylamine substitues, procede de preparation et utilisation
TW201602089A (zh) 多環性herg活化劑
CN101094827B (zh) 具有两个或更多取代基的苯化合物
JPWO2004048341A1 (ja) 新規ヘテロアリール誘導体
JPWO1999024424A1 (ja) ピラゾール化合物およびその医薬用途
JPWO2001060819A1 (ja) 新規イソキサゾール及びチアゾール化合物、並びにその医薬としての使用